Vol 2 Issue 1

Download PDF

Featuring

Issue Spotlight: The Cell & Gene Therapy Manufacturing Pathway: Part 1
Other articles

The Cell & Gene Therapy Manufacturing Pathway: Part 1

Guest Editor:

Peter Zandstra, Professor & Director, School of Biomedical Engineering at University of British Columbia

Foreword

Spotlight on the cell & gene therapy manufacturing pathway

Chris Mason, Elisa Manzotti

21 March 2016

Read

Expert Insight

Evolving product attributes through the lens of MSC translation

Robert Deans

21 March 2016

Read

Drivers and methodologies for making cell therapy process changes

Gregory Russotti

21 March 2016

Read

Centralized or decentralized manufacturing? Key business model considerations for cell therapies

Nicholas Medcalf

21 March 2016

Read

Cell and gene therapy manufacturing: the necessity for a cost-based development approach

S Callens, J Hasan, R McCoy et al.

21 March 2016

Read

Perspective

Toward a scalable and consistent manufacturing process for the production of human MSCs

Qasim Rafiq

21 March 2016

Read

Key considerations in optimizing pluripotent stem cell bioprocessing

Iwan Roberts

21 March 2016

Read

Innovator Insight

Translational cell & gene therapy collaborations: accelerating time to market

Cindy Collins

21 March 2016

Read

Journal articles

Research Article

Characterization of Rhesus Macaque lung-resident multipotent stromal cells

21 March 2016

Read

Innovator Insight

Cell and Gene Therapy World

Emily Culme-Seymour, Alexey Bersenev

21 March 2016

Read

Interview

Dr James Shapiro: the hype, hope & reality of cell therapy for diabetes

James Shapiro

21 March 2016

Read

Commercial Insights

CELL AND GENE THERAPY INSIGHTS

January 2016 Issue

Vol 2 Issue 1

Featuring

SPOTLIGHT

The Cell & Gene Therapy Manufacturing Pathway: Part 1

Foreword

Spotlight on the cell & gene therapy manufacturing pathway

Expert Insight

Evolving product attributes through the lens of MSC translation

Drivers and methodologies for making cell therapy process changes

Centralized or decentralized manufacturing? Key business model considerations for cell therapies

Cell and gene therapy manufacturing: the necessity for a cost-based development approach

Perspective

Toward a scalable and consistent manufacturing process for the production of human MSCs

Key considerations in optimizing pluripotent stem cell bioprocessing

Innovator Insight

Translational cell & gene therapy collaborations: accelerating time to market

Journal articles

Research Article

Characterization of Rhesus Macaque lung-resident multipotent stromal cells

Innovator Insight

Cell and Gene Therapy World

Interview

Dr James Shapiro: the hype, hope & reality of cell therapy for diabetes

Commercial Insights

Non-viral vectors for gene therapy

Commercial Insight – February 2016

Clinical Trial Insight: Cell and Gene therapy Q1

Stem cell community loses a treasured friend